Q2 26/27

Wockhardt (WOCKPHARMA) Q2 26/27 earnings summary

Event summary combining transcript, slides, and related documents.

Q2 26/27 earnings summary

2 Nov, 2026

Q2 and H1 results for the period ended September 30, 2026, were approved by the Board; statutory auditors issued limited review conclusions on the standalone and consolidated results.
Consolidated Q2 revenue from operations was Rs 969 crore and H1 revenue was Rs 1,898 crore; standalone H1 net profit was Rs 207 crore.

Consolidated Q2 revenue from operations was Rs 969 crore vs Rs 782 crore YoY; H1 revenue was Rs 1,898 crore vs Rs 1,520 crore.
Consolidated Q2 PBT before exceptional items was Rs 73 crore vs Rs 91 crore YoY; H1 PBT was Rs 189 crore vs a reported loss of Rs 18 crore in H1 FY26.
Standalone Q2 revenue from operations was Rs 580 crore vs Rs 380 crore YoY; H1 revenue was Rs 1,141 crore vs Rs 793 crore.
Standalone H1 net profit was Rs 207 crore vs Rs 123 crore YoY; Q2 net profit was Rs 100 crore vs Rs 54 crore.

Operations are exclusively in the pharmaceutical business segment, on both standalone and consolidated bases.

Partial view of Summaries dataset, powered by Quartr API

AI can get things wrong. Verify important information.

All investor relations material. One API.